Author

R. Boidot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Das Gupta· 1 shared A. Desai· 1 shared A. J. Smith· 1 shared A. S. Mansfield· 1 shared A. T. Nelczyk· 1 shared C. P. Schane· 1 shared C. Truntzer· 1 shared E. C. Fink· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Das Gupta

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progression

H. E. V. Gamage, S. H. Shahoei, S. T. Albright, Y. Wang, A. J. Smith, R. Farmer, E. C. Fink, E. Jacquin, E. Weisser, R. O. Bautista, M. A. Henn, C. P. Schane, A. T. Nelczyk, L. Ma, A. Das Gupta, , E. R. Nelson

This paper shows that NR0B2 in myeloid cells reduces Treg expansion and tumor growth by modulating the NLRP3 inflammasome, with small molecule agonists improving ICB efficacy in breast cancer.

bioRxiv · Aug 14, 2023 · PreprintCancer Biology

Effects of tumor mutation burden on the antigen presentation pathway

E. M. Garcia-Rivera, J. Park, A. Desai, R. Boidot, S. Chevrier, C. Truntzer, F. Ghiringhelli, M. Borad, A. S. Mansfield

The paper examines how tumor mutation burden affects antigen presentation pathway genes and finds that APG mutations are linked to improved progression-free survival with PD-1 inhibitors.

bioRxiv · Apr 14, 2021 · PreprintImmunology